Abivax S.A. announced that its Annual Ordinary and Extraordinary General Meeting will be held on May 11, 2026, at 3:00 PM CEST in Paris, with preparatory documents now available to shareholders.
Key takeaways
The General Meeting is scheduled for May 11, 2026, at 3:00 PM CEST at the Hotel Paris Marriott Opera Ambassador.
The preliminary notice of meeting and draft resolutions were published in the BALO on April 3, 2026.
Shareholder preparatory documents are available on the Company's website in accordance with French regulations.
Lead drug candidate obefazimod (ABX464) is currently in Phase 3 clinical trials for ulcerative colitis.